How stress affects immunotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at whether chronic stress changes how well immunotherapy (ICI therapy) works in people with esophageal cancer. It may help doctors understand who benefits most from treatment and how stress could affect outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75
- You have esophageal cancer confirmed by pathology (biopsy or surgery diagnosis)
- Your study team can get tumor tissue samples for testing
- You have at least one measurable tumor spot they can track using standard scan rules
- You have not yet had full-course anti-cancer treatment for advanced or metastatic chest tumors
- Your heart testing, blood counts, and kidney/liver tests meet the study’s limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with esophageal squamous cell carcinoma to see how changes in the “tumor neighborhood” may affect how well treatment works before surgery. If you’re eligible, you would receive chemotherapy plus immunotherapy as neoadjuvant (before-surgery) treatment.
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial compares two approaches for people with esophageal cancer that has shrunk or disappeared after initial chemotherapy combined with immunotherapy. It looks at whether adding targeted radiation (DCRT) or surgery is better. The goal is to find the most effective next step for eligible patients.
This study examines specific immune cell patterns in lymph nodes to predict how well PD-1 immunotherapy (a type of cancer-fighting treatment) will work for advanced or recurrent esophageal cancer. The goal is to better understand which patients will benefit most from this treatment.
This trial tests whether adding immunotherapy to standard chemoradiation (chemotherapy plus radiation) can help preserve the esophagus and avoid surgery in people with resectable esophageal cancer. It aims to see if this combination is safer and more effective than current treatment.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.